Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase II Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)

Compass Therapeutics, Inc. announced that the FDA has cleared its IND application for CTX-009, enabling the company to initiate a global Phase II clinical trial for CTX-009 in patients who have advanced Biliary Tract Cancers in the United States and South Korea.